Can your Tumor's DNA guide a better cancer treatment?
NCT ID NCT03089554
First seen Jun 01, 2026 · Last updated Jun 19, 2026 · Updated 5 times
Summary
This study is for people with advanced cancer who have run out of standard treatment options. Researchers will analyze the genetic makeup of each patient's tumor and recommend a targeted therapy based on those results. The goal is to see if this personalized approach can slow down cancer growth and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Markey Cancer Center, University of Kentucky
RECRUITINGLexington, Kentucky, 40536, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
targeted therapy drugs based on tumor genetic testing
What this could lead to
If successful, this could show that matching cancer treatments to a patient's unique tumor genetics helps control advanced cancers that have stopped responding to standard therapy.
What could go wrong
This is a small, early-phase study (93 people) with no control group, so results may not apply broadly. The targeted therapies may not work for all tumor types, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.